Home Online Features Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
Press Releases
Johnson & Johnson  
May 1, 2025

Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older

The Bradford Era

Local & Social
Latest news for you
ePaper
google_play
app_store
This Week's Ads
Current e-Edition
ePaper
google_play
app_store
Already a subscriber? Click the image to view the latest e-edition.
Don't have a subscription? Click here to see our subscription options.
Mobile App

Download Now

The Bradford Era mobile app brings you the latest local breaking news, updates, and more. Read the Bradford Era on your mobile device just as it appears in print.

ePaper
google_play
app_store
Trending Recipes

Help Our Community

Please help local businesses by taking an online survey to help us navigate through these unprecedented times. None of the responses will be shared or used for any other purpose except to better serve our community. The survey is at: www.pulsepoll.com $1,000 is being awarded. Everyone completing the survey will be able to enter a contest to Win as our way of saying, "Thank You" for your time. Thank You!

Get in touch with The Bradford Era
Submit Content
Advertise
Subscribe
Illinois
Indiana
Iowa
Michigan
New York
Pennsylvania
© Copyright The Bradford Era 43 Main St, Bradford, PA  | Terms of Use  | Privacy Policy
Powered by TECNAVIA